The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis

Zhao, Shu; Zhang, Minghui; Meng, Hongxue; Wang, Yan; Liu, Yupeng; Jing, Jing; Huang, Lan; Sun, Mengqi; Zhang, Yue; Zhang, Qingyuan

doi:10.20892/j.issn.2095-3941.2018.0047

Cited by 20 publications

(11 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many of the genes are found to play different roles through different mechanisms in different cancers. 53 – 56 Similarly, Siglec-15 has variable prognostic significance in diverse cancers, and even in different subtypes of the same cancer. It is well accepted that tumor heterogeneity is a major challenge in cancer treatment.…”

Section: Discussionmentioning

confidence: 99%

Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis

Zhang

Wang

et al. 2020

OncoImmunology

View full text Add to dashboard Cite

Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) is considered a novel anti-tumor target comparable to programmed cell death 1 ligand 1(PD-L1). However, little is known about Siglec-15. Our study aims to understand its expression signature, prognosis value, immune infiltration pattern, and biological function using multi-omic bioinformatics from public databases and verify them in lung cancer patients. Integrated analysis of The Cancer Genome Atlas and Genotype-Tissue Expression portals showed Siglec-15 was overexpressed across cancers. Genetic and epigenetic alteration analysis was performed using cBioportal and UALCAN, showed Siglec-15 was regulated at the genetic and epigenetic levels. Survival estimated using Kaplan-Meier plotter indicated high Siglec-15 expression correlated with favorable or unfavorable outcomes depending on the different type and subtype of cancer. Components of immune microenvironment were analyzed using CIBERSORT, and the correlation between immune cells and Siglec-15 was found to be distinct across cancer types. Based on Gene Set Enrichment Analysis, Siglec-15 was implicated in pathways involved in immunity, metabolism, cancer, and infectious diseases. Lung cancer patients with positive Siglec-15 expression showed significantly short survival rates in progressionfree survival concomitant with reduced infiltration of CD20 + B, and dendritic cells by immunohistochemistry. Quantitative real-time PCR results indicated the overexpression of Siglec-15 was correlated with activation of the chemokine signaling pathway. In conclusion, Siglec-15 could serve as a vital prognostic biomarker and play an immune-regulatory role in tumors. These results provide us with clues to better understand Siglec-15 from the perspective of bioinformatics and highlight the importance of Siglec-15 in many types of cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis

Zhang

Wang

et al. 2020

OncoImmunology

View full text Add to dashboard Cite

show abstract

“…Oncomine results were largely consistent with the results of these analyses. Many genes play different roles in different cancers (58)(59)(60), thus explaining the variable prognostic significance of ASF1B observed among cancer types and subtypes. Such tumor heterogeneity is a significant barrier to reliable tumor treatment [61][62][63].…”

Section: Discussionmentioning

confidence: 99%

ASF1B Promotes Oncogenesis in Lung Adenocarcinoma and Other Cancer Types

et al. 2021

View full text Add to dashboard Cite

Anti-silencing function 1B histone chaperone (ASF1B) is known to be an important modulator of oncogenic processes, yet its role in lung adenocarcinoma (LUAD) remains to be defined. In this study, an integrated assessment of The Cancer Genome Atlas (TCGA) and genotype-tissue expression (GTEx) datasets revealed the overexpression of ASF1B in all analyzed cancer types other than LAML. Genetic, epigenetic, microsatellite instability (MSI), and tumor mutational burden (TMB) analysis showed that ASF1B was regulated by single or multiple factors. Kaplan-Meier survival curves suggested that elevated ASF1B expression was associated with better or worse survival in a cancer type-dependent manner. The CIBERSORT algorithm was used to evaluate immune microenvironment composition, and distinct correlations between ASF1B expression and immune cell infiltration were evident when comparing tumor and normal tissue samples. Gene set enrichment analysis (GSEA) indicated that ASF1B was associated with proliferation- and immunity-related pathways. Knocking down ASF1B impaired the proliferation, affected cell cycle distribution, and induced cell apoptosis in LUAD cell lines. In contrast, ASF1B overexpression had no impact on the malignant characteristics of LUAD cells. At the mechanistic level, ASF1B served as an indirect regulator of DNA Polymerase Epsilon 3, Accessory Subunit (POLE3), CDC28 protein kinase regulatory subunit 1(CKS1B), Dihydrofolate reductase (DHFR), as established through proteomic profiling and Immunoprecipitation-Mass Spectrometry (IP-MS) analyses. Overall, these data suggested that ASF1B serves as a tumor promoter and potential target for cancer therapy and provided us with clues to better understand the importance of ASF1B in many types of cancer.

show abstract

“…A number of previous studies also reported the prognostic significance of PD-L1 in various cancers. A recent meta-analysis including 2,005 patients showed that high PD-L1 expression was associated with a poor prognosis (HR = 2.04, 95% CI = 1.18–3.54, p = 0.01) in non-Hodgkin lymphoma (Zhao et al, 2018). Li’s study showed that PD-L1 overexpression could foresee worse OS and DFS in hepatocellular carcinoma (Li et al, 2018a).…”

Section: Discussionmentioning

confidence: 99%

Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis

Zhu

Sun²,

Ling

et al. 2019

Front. Pharmacol.

View full text Add to dashboard Cite

Background: The prognostic role of programmed cell death-ligand 1 (PD-L1) in bladder cancer has been investigated in previous studies, but the results remain inconclusive. Therefore, we carried out a meta-analysis to evaluate the prognostic significance of PD-L1 in patients with bladder cancer. Methods: The electronic databases PubMed, Embase, Web of Science, and Cochrane Library were searched. The association between PD-L1 expression and survival outcomes and clinicopathological factors was analyzed by hazard ratios (HRs) or odds ratios (ORs) and 95% confidence intervals (CIs). Results: A total of 11 studies containing 1,697 patients were included in the meta-analysis. High PD-L1 expression was associated with poor overall survival (OS) (HR = 1.83, 95% CI = 1.24–2.71, p = 0.002). There was nonsignificant association between PD-L1 and recurrence-free survival (RFS) (HR = 1.43, 95% CI = 0.89–2.29, p = 0.134), cancer-specific survival (CSS) (HR = 1.51, 95% CI = 0.80–2.87, p = 0.203), or disease-free survival (DFS) (HR = 1.53, 95% CI = 0.88–2.65, p = 0.13). Furthermore, high PD-L1 was significantly correlated with higher tumor stage (OR = 3.9, 95% CI = 2.71–5.61, p < 0.001) and distant metastasis (OR = 2.5, 95% CI = 1.22–5.1, p = 0.012), while PD-L1 overexpression was not correlated with sex, tumor grade, lymph node status, and multifocality. Conclusions: The meta-analysis suggested that PD-L1 overexpression could predict worse survival outcomes in bladder cancer. High PD-L1 expression may act as a potential prognostic marker for patients with bladder cancer.

show abstract

The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis

Cited by 20 publications

References 29 publications

Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis

Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis

ASF1B Promotes Oncogenesis in Lung Adenocarcinoma and Other Cancer Types

Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis

Contact Info

Product

Resources

About